Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients.

ABSTRACT:

Aims

Chloroquine (CQ) has been repurposed to treat coronavirus disease 2019 (COVID-19). Understanding the pharmacokinetics (PK) in COVID-19 patients is essential to study its exposure-efficacy/safety relationship and provide a basis for a possible dosing regimen optimization.

Subject and methods

In this study, we used a population-based meta-analysis approach to develop a population PK model to characterize the CQ PK in COVID-19 patients. An open-label, single-center study (ethical review approval number: PJ-NBEY-KY-2020-063-01) was conducted to assess the safety, efficacy, and pharmacokinetics of CQ in patients with COVID-19. The sparse PK data from 50 COVID-19 patients, receiving 500 mg CQ phosphate twice daily for 7 days, were combined with additional CQ PK data from 18 p

SUBMITTER: Yao X 

PROVIDER: S-EPMC7665884 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature